Novartis Pulling Out All The Stops To Amp Up Entresto Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has set a sales goal of $200m for Entresto in 2016, not an enormous amount for a drug that is expected to eventually be a multi-billion dollar seller, but ambitious given its slow first quarter start.
You may also be interested in...
2Q Pharma Results Preview: What Lies Ahead
The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.
Lilly’s Psoriasis Drug Taltz Set For Second Quarter Launch
Ixekizumab had a smooth FDA approval, with no advisory committee needed for the second member of the IL-17 inhibitor class.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.